Now a third option is available after the U.S. Food and Drug Administration last week approved Vertex Pharmaceuticals’ Suzetrigine, sold as twice-daily Journavx, a non-addictive prescription drug for ...
A new painkiller that is said to be free of addiction risks may be transformative for treatment of acute pain, according to local medical professionals. "I think it could be a potentially ...
The Food and Drug Administration on Thursday approved Journavx, a non-opioid painkiller that is the first novel pain drug to win government authorization in more than 20 years. Vertex ...
Vertex Pharmaceuticals ( VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and ...
The FDA has approved a new non-opioid prescription medication, Journavx for adults with moderate to severe acute pain.
Journavx is a newly-aproved painkiller that experts say could help Long Island's opioid epidemic. NewsdayTV's Virginia Huie reports.
Want a say in the news? Email Claudia at [email protected] to have your thoughts on the stories covered here or on ...
The opioid epidemic continues to affect hundreds of thousands of people, but there may be hope for the future with a new, non ...
Vertex Pharmaceuticals (NASDAQ:VRTX), a leading biotechnology company known for its cystic fibrosis (CF) treatments, is at a critical juncture as it seeks to diversify its portfolio and maintain its ...
The first shot taken at Medicaid, likely UnitedHealthcare coverage for Vertex's pain drug, and Optum’s wellness visit ad.
These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...
The Food and Drug Administration (FDA) is hoping a newly approved non-opioid pain medication could help save lives. Dr.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback